Cerevel Therapeutics (NASDAQ: CERE)
Some price data may be temporarily unavailable.
Cerevel Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cerevel Therapeutics Company Info
Cerevel Therapeutics is a clinical-stage biotechnology business focusing exclusively on central nervous system disorders, which is a major global market.
News & Analysis
Why Shares of Cerevel Therapeutics Are Dropping Wednesday
The company reported second-quarter earnings.
3 Biotech Stocks That Soared to New Heights Last Week
Find out what these industry favorites are doing to impress investors.
Why Cerevel Therapeutics Is Up More Than 29% in the First Half of 2021
A positive early stage trial for a schizophrenia drug has pushed this biotech's stock this year.
Here's What's Pushing Cerevel Therapeutics Stock Lower Today
Investors aren't thrilled about how this biotech intends to pay operating expenses that are about to balloon.
These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday
You might not have heard of them, but one went up big while the other served up a massive disappointment.
Here's Why Cerevel Therapeutics Stock Is Shooting Through the Roof Today
Positive topline results from the company's schizophrenia candidate were better than expected.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.